Literature DB >> 8348266

Antiribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus.

L S Teh1, M K Lee, F Wang, M Manivasagar, P J Charles, G D Nicholson, E M Hay, D A Isenberg, N Amos, B D Williams.   

Abstract

We report a significantly increased prevalence of antiribosomal P protein antibodies in Malaysian Chinese patients (38%) with SLE compared to white Caucasian (13%) and Afro-Caribbean (20%) patients. The increased prevalence was not due to a generalized increase in autoantibody production because anti-dsDNA and anti-SSA antibodies were present in comparable frequencies in the three ethnic groups while anti-Sm and anti-SSB antibodies were rarely found in the Malaysian Chinese patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348266     DOI: 10.1093/rheumatology/32.8.663

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  13 in total

1.  Technical and clinical evaluation of anti-ribosomal P protein immunoassays.

Authors:  M Mahler; K Kessenbrock; J Raats; M J Fritzler
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus.

Authors:  J L J Lin; V Dubljevic; M J Fritzler; Ban-Hock Toh
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

3.  Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides.

Authors:  Latisha D Heinlen; Lauren L Ritterhouse; Micah T McClain; Michael P Keith; Barbara R Neas; John B Harley; Judith A James
Journal:  J Mol Med (Berl)       Date:  2010-04-17       Impact factor: 4.599

4.  The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease.

Authors:  A G Tzioufas; N G Tzortzakis; E Panou-Pomonis; K A Boki; M Sakarellos-Daitsiotis; C Sakarellos; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

5.  International multicenter evaluation of autoantibodies to ribosomal P proteins.

Authors:  Michael Mahler; Kai Kessenbrock; Magdalena Szmyrka; Yoshinari Takasaki; Ignacio Garcia-De La Torre; Yehuda Shoenfeld; Falk Hiepe; Chen Shun-le; Carlos A von Mühlen; Henning Locht; Peter Höpfl; Allan Wiik; Westley Reeves; Marvin J Fritzler
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Anti-ribosomal antibodies from lupus patients bind DNA.

Authors:  L Caponi; D Chimenti; F Pratesi; P Migliorini
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

7.  Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus.

Authors:  Ahmed M Abdel-Nasser; Rasha M Ghaleb; Jehan A Mahmoud; Wafaa Khairy; Refaat M Mahmoud
Journal:  Clin Rheumatol       Date:  2008-05-15       Impact factor: 2.980

8.  Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus.

Authors:  Jing Li; Ying Shen; Jing He; Rulin Jia; Xiujie Wang; Xiaosan Chen; Dahai Wang; Lei Han; Lei Zhu; Xiaofeng Chi; Sandra Saschenbrecker; Cornelia Dähnrich; Winfried Stöcker; Wolfgang Schlumberger; Zhan-Guo Li
Journal:  J Clin Lab Anal       Date:  2013-02-11       Impact factor: 2.352

9.  Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus.

Authors:  Yong-Jun Mei; Peng Wang; Chao Jiang; Tao Wang; Lin-Jie Chen; Zhi-Jun Li; Hai-Feng Pan
Journal:  Clin Rheumatol       Date:  2017-11-18       Impact factor: 2.980

10.  Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus.

Authors:  Deanna M Santer; Taku Yoshio; Seiji Minota; Thomas Möller; Keith B Elkon
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.